Evidence Grade C — Moderate human evidence. 31 published studies, 18 human. 1 registered clinical trial.
Medically reviewed by a licensed medical professional
CJC-1295 (without DAC) is a synthetic modified fragment of growth hormone-releasing hormone designed to resist enzymatic breakdown, stimulating the pituitary gland to release growth hormone. It has no approval from any regulatory agency and no Phase III trials have been completed. It is widely available through unregulated sources, often combined with ipamorelin.
CJC-1295 is also known by these brand and alternate names:
31 published studies: 18 human, 5 animal, 4 in-vitro, 8 reviews
CJC-1295 (without DAC) has no marketing authorisation from any regulatory agency. Limited Phase I pharmacokinetic data showed increased growth hormone levels following single injections. No Phase III trials have been conducted.
CJC-1295 is widely available through unregulated channels, often in combination with ipamorelin. These combinations have no clinical trial support. Products from unregulated sources lack pharmaceutical quality assurance. The compound should be distinguished from CJC-1295 DAC (#90), which has a different pharmacokinetic profile.
Research suggests CJC-1295 binds the GHRH receptor on pituitary cells, stimulating growth hormone release. The four amino acid substitutions protect the peptide from the enzyme DPP-IV that rapidly degrades native GHRH. These observations come from limited early-phase human pharmacokinetic data and animal studies. The clinical significance of these effects has not been established in controlled trials.
Research is limited to early-phase pharmacokinetic data showing that CJC-1295 increases growth hormone levels after single injections. No efficacy trials have been conducted for any clinical outcome. The commonly used combination with ipamorelin has no clinical trial support whatsoever. Safety concerns include potential pituitary desensitisation with repeated use, unknown effects of sustained IGF-1 elevation (including theoretical cancer risk), and cortisol co-stimulation. A death was reported in a 2006 clinical trial of the DAC (Drug Affinity Complex) version, though causality was not established. Products from unregulated sources lack pharmaceutical quality assurance.
PeptideTrace tracks 1 registered clinical trial for CJC-1295 sourced from ClinicalTrials.gov.
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
CJC-1295 (modified GRF 1-29) is a synthetic 30-amino-acid GHRH analogue, MW ~3,367 Da. First 29 AA of GHRH with four substitutions (D-Ala2, Gln8, Ala15, Met(O)27) for DPP-IV/protease resistance. Without DAC: half-life ~30 minutes. Not approved. Often combined with ipamorelin in grey-market.
Research suggests binding to GHRH-R (class B GPCR) on pituitary somatotrophs. Gs/cAMP/PKA signaling stimulates pulsatile GH release mirroring physiology. Four substitutions protect against DPP-IV cleavage. Animal studies indicate increased GH pulse amplitude without altered frequency.
No marketing authorization. Teichman et al. (JCEM 2006; N=21): single SC injection increased GH 2-10-fold for up to 6 hours. No Phase III. Grey-market: 100-300 mcg SC with ipamorelin, not clinically validated.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 44 vendor listings
View pricing data across vendors and countries for CJC-1295
Somatrogon is marketed as Ngenla (approved June 2023) for paediatric growth hormone deficiency in children aged 3 years and older. In the pivotal trial, once-weekly somatrogon produced growth rates equivalent to daily somatropin injections (10.1 cm/year versus 9.8 cm/year), confirming that reducing injection frequency does not compromise growth outcomes. Ngenla represents a meaningful advance for paediatric patients and their families, reducing injections from 365 to 52 per year. Treatment adherence has been a persistent challenge with daily growth hormone, and weekly dosing is expected to improve long-term outcomes through better compliance. Somatrogon competes directly with somapacitan (Sogroya), the other approved weekly growth hormone, creating a new generation of less burdensome treatment options.
Somapacitan is marketed as Sogroya (approved August 2020 for adult growth hormone deficiency; expanded April 2023 to paediatric growth hormone deficiency in children aged 2.5 years and older). It is the first once-weekly growth hormone approved for both adult and paediatric patients. In adults, clinical trials showed improvements in body composition including reduced truncal fat. In children, growth rates were comparable to daily somatropin. The albumin-binding approach provides predictable drug levels with lower peak-to-trough variation than some other long-acting growth hormone technologies. Sogroya competes with somatrogon (Ngenla) in the growing once-weekly growth hormone market, with both products expected to gradually replace daily injections as the standard of care.
ACE-031 has no marketing authorisation. A Phase I trial in healthy women showed increased lean mass and decreased fat mass. A Phase II trial in DMD (24 patients) showed lean body mass increases but was discontinued due to bleeding-related safety concerns (epistaxis, telangiectasias, and gum bleeding), likely caused by inhibition of BMP-9/10 vascular signalling. ACE-031 is a large fusion protein (~90 kDa), not a peptide. Its clinical development was halted. The non-selective ligand-trapping profile — capturing beneficial vascular signalling molecules alongside the intended muscle-growth targets — illustrates the challenge of targeting the TGF-beta superfamily. Acceleron subsequently developed more selective agents.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
